Bio-Rad Laboratories, Inc.
Financials
Valuation Metrics
Bio-Rad Laboratories, Inc.'s Market Cap is $9.80B. At end of 2025 it was $8.17B. Ranked #908 of 3,118 in US market (top 29%), #627 of 1,644 on NYSE (top 38%), #68 of 203 in Health Care Equipment & Services (top 33%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.80B | US#908/3,118 Sec#68/203 |
| Revenue | $2.59B | US#1,273/3,118 Sec#81/203 |
| Net Income | $222M | US#1,231/3,118 Sec#62/203 |
| Total Assets | $10.25B | US#978/3,118 Sec#48/203 |
| Net Assets | $7.17B | US#542/3,118 Sec#33/203 |
| Employees | 7,450 | US#1,011/3,118 Sec#78/203 |
| Value | ||
| P/E | 44.07x | US#1,860/3,118 Sec#92/203 |
| P/B | 1.37x | US#813/3,118 Sec#33/203 |
| P/S | 3.78x | US#2,039/3,118 Sec#136/203 |
| EV/EBITDA | 19.62x | US#1,902/3,118 Sec#87/203 |
| FCF Yield | 3.60% | US#1,698/3,118 Sec#92/203 |
| Profitability | ||
| ROE | 3.10% | US#1,946/3,118 Sec#102/203 |
| ROA | 2.17% | US#1,587/3,118 Sec#98/203 |
| Op. Margin | 9.08% | US#1,652/3,118 Sec#86/203 |
| Revenue Growth | 1.37% | US#2,100/3,118 Sec#158/203 |
| Earnings Growth | -30.32% | US#1,606/3,118 Sec#85/203 |
| Financial Health | ||
| Debt Ratio | 42.91% | US#486/3,118 Sec#53/203 |
| Total Debt | $1.20B | US#1,422/3,118 Sec#77/203 |
| FCF | $353M | US#1,063/3,118 Sec#62/203 |
| Cash | $517M | US#1,048/3,118 Sec#59/203 |
| Current Ratio | 3.14x | US#735/3,118 Sec#73/203 |
| Net Debt/EBITDA | 1.28x | US#1,079/3,118 Sec#65/203 |
| Dividend | ||
| Div. Yield | 0.50% | US#1,528/3,118 Sec#41/203 |
| Performance | ||
| 1Y Return | 14.60% | US#1,070/3,118 Sec#89/203 |
| 1M Return | -0.79% | US#1,914/3,118 Sec#145/203 |
| From 52W High | -7.58% | US#506/3,118 Sec#48/203 |
| 1Y MDD | -27.24% | US#1,096/3,118 Sec#44/203 |
| Trading | ||
| Volume | 155,244 shares | US#2,792/3,118 Sec#190/203 |
| Trading Value | $57M | US#1,309/3,118 Sec#93/203 |
| Per Share | ||
| EPS | $8.31 | US#379/3,118 Sec#25/203 |
| BPS | $268.07 | US#16/3,118 Sec#1/203 |
Company Info
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.